دورية أكاديمية
أعرض في EDS

Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study.

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study.
المؤلفون: Liang P; Department of General Surgery, The Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China., Tang QL; Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China., Lin T; Department of Urology, Liaocheng People's Hospital, Liaocheng, Shandong, China., Tang ZK; Department of Clinical Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu, China., Liu FD; Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China., Zhou XZ; Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China., Tao RZ; Department of Urology, The Affiliated Jiangning Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
المصدر: Frontiers in neuroscience [Front Neurosci] 2024 Apr 10; Vol. 18, pp. 1373375. Date of Electronic Publication: 2024 Apr 10 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101478481 Publication Model: eCollection Cited Medium: Print ISSN: 1662-4548 (Print) Linking ISSN: 1662453X NLM ISO Abbreviation: Front Neurosci Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Lausanne : Frontiers Research Foundation
مستخلص: Objective: To observe the efficacy and safety of pelvic floor magnetic stimulation (PFMS) combined with mirabegron in female patients with refractory overactive bladder (OAB) symptoms.
Patients and Methods: A total of 160 female patients with refractory OAB symptoms were prospectively randomized into two groups. Eighty cases in the combination group accepted PFMS and mirabegron therapy and 80 cases as control only accepted mirabegron therapy (The clinical trial registry number: ChiCTR2200070171). The lower urinary tract symptoms, OAB questionnaire (OAB-q) health-related quality of life (HRQol), symptom bother score and OABSS between two groups were compared at the 1st, 2nd and 4th week ends.
Results: All of 160 patients were randomly assigned to two groups, of which 80 patients were included in the combination group and 80 in the mirabegron group. The incidences of LUTS, including urgency, frequent urination, and incontinence episodes, in the 2nd week and the 4th week after combination treatment were significantly lower than those in the mirabegron group ( p  < 0.05). The incidence of drug-related adverse events between two groups was similar, and there was no statistically significant difference ( p  > 0.05). With respect to secondary variables, the OAB-q HRQol score in the combination group was statistically superior in comparison with that in the mirabegron group between the 2nd week and the 4th week ( p  < 0.05). This was consistent with the primary outcome. Meanwhile, from the second to fourth week, the OAB-q symptom bother score and OABSS in the combination group were both lower than in the mirabegron group ( p  < 0.05).
Conclusion: Combination therapy of PFMS and mirabegron demonstrated significant improvements over mirabegron monotherapy in reducing refractory OAB symptoms for female patients, and providing a higher quality of life without increasing bothersome adverse effects.
Clinical Trial Registration: https://www.chictr.org.cn/, ChiCTR-INR-22013524.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer HC declared a shared affiliation with the authors R-zT and Z-kT to the handling editor at the time of review.
(Copyright © 2024 Liang, Tang, Lin, Tang, Liu, Zhou and Tao.)
References: Adv Exp Med Biol. 2003;539(Pt A):281-91. (PMID: 15088911)
Am J Obstet Gynecol. 2014 Nov;211(5):561.e1-5. (PMID: 25019486)
Int Braz J Urol. 2016 May-Jun;42(3):487-93. (PMID: 27286111)
World J Urol. 2021 Dec;39(12):4465-4470. (PMID: 34241685)
PLoS One. 2013 Oct 01;8(10):e76706. (PMID: 24098552)
Neurourol Urodyn. 2011 Nov;30(8):1448-55. (PMID: 21826714)
J Urol. 1992 Mar;147(3):658-61. (PMID: 1538450)
Neurourol Urodyn. 2018 Apr;37(4):1220-1240. (PMID: 29441607)
Urology. 1997 Dec;50(6A Suppl):36-52; discussion 53-6. (PMID: 9426749)
J Urol. 2019 Mar;201(3):573-580. (PMID: 30240691)
Neurourol Urodyn. 2024 Feb;43(2):396-406. (PMID: 38149719)
Neurorehabil Neural Repair. 2011 Jul-Aug;25(6):570-6. (PMID: 21411715)
BJU Int. 2014 Jun;113(6):847-8. (PMID: 24905658)
Int Urogynecol J. 2017 Mar;28(3):351-359. (PMID: 27613622)
Physiol Rev. 2013 Apr;93(2):653-80. (PMID: 23589830)
Neurourol Urodyn. 2018 Jun;37(S4):S108-S116. (PMID: 30133790)
Adv Ther. 2020 Feb;37(2):637-643. (PMID: 31875299)
Neurourol Urodyn. 2010;29(1):4-20. (PMID: 19941278)
Can Urol Assoc J. 2017 May;11(5):E142-E173. (PMID: 28503229)
Gynecol Obstet Invest. 2018;83(2):140-144. (PMID: 28637031)
Naunyn Schmiedebergs Arch Pharmacol. 2013 Mar;386(3):177-83. (PMID: 23263450)
Sci Rep. 2022 Nov 7;12(1):18844. (PMID: 36344629)
Int Urogynecol J Pelvic Floor Dysfunct. 2007 Aug;18(8):875-80. (PMID: 17136485)
فهرسة مساهمة: Keywords: combination therapy; incontinence; mirabegron; pelvic floor magnetic stimulation; refractory overactive bladder
تواريخ الأحداث: Date Created: 20240425 Latest Revision: 20240426
رمز التحديث: 20240426
مُعرف محوري في PubMed: PMC11040079
DOI: 10.3389/fnins.2024.1373375
PMID: 38660220
قاعدة البيانات: MEDLINE
الوصف
تدمد:1662-4548
DOI:10.3389/fnins.2024.1373375